Posters

Can we trust in Tropicamide or Cyclopentolate for eye biometric measurement and intraocular lens calculation?

Poster Details

First Author: A.Urkia Solorzano SPAIN

Co Author(s):    S. Diaz   J. Orbegozo   I. Basterra   A. Pérez           

Abstract Details

Purpose:

To assess possible differences between eye parameters measured by IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) biometer before dilatating the pupil and after the use of tropicamide or cyclopentolate for dilatation. A prospective observational study was carried out including 135 eyes (67 right and 68 left) of 70 patients, 55.71% women and 44.28% men, who underwent a cataract surgery and presented no other intraocular diseases. The effect of these changes on intraocular lens (IOL) power for emmetropia was also analysed.

Setting:

Centro Oftalmológico Integral, Rodríguez Arias 6º, Bilbao (Basque Country), Spain.

Methods:

We analysed the anterior chamber depth (ACD), axial length (AL), lens thickness (LT), white to white distance (WTW) and total keratometry (TK) to all our 135 eyes. A second measurement was taken after de use of tropicamide in one group of 78 eyes; and after the use of cyclopentolate in another group of 57 eyes to determine any possible variation in the same eye parameters. We also analysed the impact on the intraocular lens power choice for emmetropia calculated with the Haigis, Barrett, Holladay 2 and Sanders/Retzlaff/Kraff Theoretical (SRK/T) formulas.

Results:

There was a statistically significant increase of ACD (+0.13 +/- 0.09 mm; p=0.007) after the use of tropicamide. No significant change was observed in AL (+0.15 +/- 0.11 mm; p=0.423), LT (-0.05 +/- 0.04 mm; p=0.283), WTW (-0.12 +/- 0.09 mm; p=0.573) and TK (-0.02 +/- 0.02 Dp; p=0.812). In the cyclopentolate group, the variation was not significant in any eye parameter measured: ACD (-0.03 +/-0.02 mm; p=0.61), AL (-0.20 +/- 0.14 mm; p=0.305), LT (+0.05 +/-0.04 mm; p=0.415), WTW (+0.14 +/- 0.10 mm; p=0.487) and TK (+0.08 +/- 0.06 Dp; p=0.323). Pupil dilatation in any group did not affect IOL power calculation based on the formulas used in our study (Haigis, Barrett, Holladay 2 and SRK/T) for targeting emmetropia.

Conclusions:

Tropicamide produces a significant increase in ACD when this parameter is measured by the IOL Master 700. This effect was not found after the use of cyclopentolate. Mydriatic drugs do not change significantly other eye parameters: AL, LT, WTW and TK. There were no differences on the IOL power calculation using the formulas: Haigis, Barrett, Holladay 2 and SRK/T.

Financial Disclosure:

None